Editorial

  1. A Possible “Humirageddon:” Perspectives On The EU Biosimilar Launch
    10/16/2018

    In the wake of the arrival of Humira biosimilars in the EU, Jorge Santos da Silva and Jennifer Heller of McKinsey & Company share several critical pricing and market considerations for companies as this highly anticipated product finally becomes available to patients.

  2. Internal And External Risks To Biosimilar Companies And The Path Forward
    10/15/2018

    There are many challenges to walk through to truly understand the opportunity, the risks, and the best path forward for biosimilars, but the best thing would be to start by recognizing the external and internal risks that likely every player in the space is facing.

  3. Biosimilar Regulatory Inefficiencies: Would Data Sharing Violate The U.S. Constitution?
    10/11/2018

    In the global biosimilars industry, regulations are administered locally, on a country-by-country basis, inevitably leading to inefficiencies and contradictions in regulatory requirements for biosimilar approval from one country to the next. If those inefficiencies are too great, some companies may delay or forego entirely seeking approval in a jurisdiction where the costs or uncertainties of the regulatory path are too high. 

  4. Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations
    10/10/2018

    I sat down with Kate Hammeke, VP of Industry Standard Research to discuss the biggest surprises or takeaways from this year’s report about the industry’s biologics and biosimilars manufacturing goals. But the conversation also evolved to some of the larger trends Hammeke expects to see impacting the biosimilar players in the future.

  5. The Humira Tsunami Cometh: What Can We Expect?
    10/9/2018

    In the first segment of this two-part Q&A article, da Silva and Heller share their perspectives on the EU market potential for Humira biosimilars, which markets they expect will be most dynamic from a competition standpoint, and what Humira biosimilar players can learn from previous tumor necrosis factor (TNF) biosimilar launches.

  6. What To Watch For In The Implementation Of FDA’s Biosimilar Action Plan
    10/3/2018

    In July 2018, the FDA unveiled a Biosimilar Action Plan (BAP) intended to “facilitate the efficient development and approval” of biosimilar products. When FDA Commissioner Scott Gottlieb introduced the BAP, he emphasized the importance of building a market for biosimilar products and expressed concern that the market is not yet established.

  7. Biosimilar Education: The Elements Of An Effective Strategy
    9/28/2018

    In this first of what I expect will be several articles, I will lay out one of the current educational gaps I’ve noticed, as well as introduce real educational examples or efforts I’ve encountered (or would like to see more of) that show promising and widely adaptable pathways forward.

  8. Off The Beaten Path: 3 Strategies For Improving World-Wide Biosimilar Access
    9/28/2018

    Low- and middle-income nations naturally demand different approaches, and, there is, of course, still much work to be done to bolster biologics use in these countries. This article continues that discussion, illuminating several specific strategies companies can explore to better reach a wide variety of countries and patients.

  9. Charting A Biosimilar Course In Low- And Middle-Income Nations
    9/26/2018

    Though entering some of these nations will not be for the faint of heart, Iyer believes the solution to these access issues is closer than we realize.

  10. Could Naïve Patients Be The Key To U.S. Biosimilar Success?
    9/26/2018

    A decade after the primary negotiations that resulted in the Biologics Price Competition and Innovation Act (BPCIA), it is safe to say the promise of biosimilars is yet to be realized. And as it turns out, perhaps naivety, in a clinical sense, is the solution.